Bifogade filer
Year End Report Stille Q4 2025
Net sales amounted to MSEK 174.9 (161.2), an increase of 8.5 percent (negative organic growth of 6.1 percent). The quarter was negatively impacted by the phase-out of non-strategic products in surgical instruments that began in early 2025 (MSEK 5.8) and a negative currency effect (MSEK 9.9). Adjusted for these two factors, underlying organic growth would have amounted to 3.7 percent.
” The supply chain situation improved during the quarter enabling us to reduce delivery time, says Ulrik Berthelsen. Looking ahead, we expect to see solid growth in 2026 driven by a combination of strong order intake, operational improvements, and commercial execution.
The gross margin was 51.1 percent (58.4) and EBITDA before non-recurring items amounted to MSEK 38.1 (46.3).
” We have a market leading portfolio of products in both surgical instruments and surgical tables and with improved product availability we will have the foundation for long-term value creation”, the Stille CEO concludes.
| MSEK | OCT-DEC 2025 | OCT-DEC 2024 | JAN-DEC 2025 | JAN-DEC 2024 |
| Net sales | 174.9 | 161.2 | 567.6 | 569.9 |
| Gross profit, % | 51.1 | 58.4 | 50.7 | 51.9 |
| EBITDA before non-recurring items | 38.1 | 46.3 | 113.8 | 142.4 |
| EBITDA before non-recurring items, % | 21.8 | 28.7 | 20.0 | 25.0 |
| EBITDA | 38.1 | 21.8 | 106.7 | 98.0 |
| EBITDA, % | 21.8 | 13.5 | 18.8 | 17.2 |
| EBIT before non-recurring items | 28.5 | 39.2 | 80.3 | 114.9 |
| EBIT before non-recurring items, % | 16.3 | 24.3 | 14.2 | 20.2 |
| EBIT | 28.5 | 14.8 | 73.2 | 70.5 |
| EBIT, % | 16.3 | 9.2 | 12.9 | 12.4 |